<DOC>
	<DOC>NCT02576652</DOC>
	<brief_summary>Bone Histomorphometry of the Proximal Femur in Denosumab-treated Subjects Undergoing Total Hip Replacement</brief_summary>
	<brief_title>Bone Histomorphometry in Subjects Undergoing Total Hip Replacement</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Demeclocycline</mesh_term>
	<criteria>Subject has provided informed consent/assent prior to initiation of any studyspecific activities/procedures Ambulatory postmenopausal women and men with osteoporosis Scheduled to undergo elective THR due to osteoarthritis of the hip Received at least 2 doses of denosumab 60 mg subcutaneously over 18 months Last dose of denosumab within 6 months of scheduled THR Received treatment for osteoporosis other than denosumab in one year prior to THR Subjects with current diagnosis of any of the following conditions are excluded Current, uncontrolled hypo or hyperthyroidism (subjects who have controlled hypo or hyperthyroidism may be eligible, provided that they have been on a stable therapy for at least 3 months [per subject report]) Current, hypo or hyperparathyroidism Osteomalacia Paget's disease of bone Other bone diseases which affect bone metabolism (eg, osteopetrosis, osteogenesis imperfecta) Severe chronic kidney disease (CKD), defined as CKD stage 4 or greater Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma) Selfreported alcohol or drug abuse within the previous 12 months Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s) Other investigational procedures while participating in this study are excluded Subject has known sensitivity to any of the products to be administered (eg, tetracycline, demeclocycline) during study Subject likely to not be available to complete all protocolrequired study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>bone biopsy</keyword>
	<keyword>tetracycline</keyword>
	<keyword>demeclocycline</keyword>
	<keyword>total hip replacement</keyword>
</DOC>